2023
Tissue-specific biological aging predicts progression in prostate cancer and acute myeloid leukemia
Ramakrishnan A, Datta I, Panja S, Patel H, Liu Y, Craige M, Chu C, Jean-Marie G, Oladoja A, Kim I, Mitrofanova A. Tissue-specific biological aging predicts progression in prostate cancer and acute myeloid leukemia. Frontiers In Oncology 2023, 13: 1222168. PMID: 37746266, PMCID: PMC10512286, DOI: 10.3389/fonc.2023.1222168.Peer-Reviewed Original ResearchAcute myeloid leukemiaProstate cancerYears of ageAML progressionCancer progressionMyeloid leukemiaStratified survival analysisBiological agingHigh Gleason scoreCox proportional hazardsMarker of progressionProstate cancer progressionPersonalized therapeutic managementMultiple cancer typesAML incidenceOverall survivalPrognostic factorsGleason scoreTherapeutic managementPatient cohortRisk scorePatientsCancer aggressivenessChronological agingProportional hazards
2022
Extended versus standard pelvic lymph node dissection yields no difference in 3-year biochemical recurrence rates
Nagaya N, Chua K, Sterling J, Horie S, Kim I. Extended versus standard pelvic lymph node dissection yields no difference in 3-year biochemical recurrence rates. Prostate International 2022, 11: 107-112. PMID: 37409090, PMCID: PMC10318318, DOI: 10.1016/j.prnil.2022.12.005.Peer-Reviewed Original ResearchStandard pelvic lymph node dissectionPelvic lymph node dissectionLymph node dissectionNode-positive patientsNode dissectionAdjuvant treatmentRecurrence rateGleason scoreSubgroup analysisNational Comprehensive Cancer Network guidelinesPSA progression-free survivalAdjuvant androgen deprivation therapyPSA recurrence rateAndrogen deprivation therapyNode-positive diseaseProgression-free survivalGleason score 8Kaplan-Meier analysisAdditional therapeutic benefitBiochemical recurrence ratePositive prostate cancerGleason score 6Time of prostatectomyDeprivation therapyMedian follow
2018
Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer
Jang T, Patel N, Faiena I, Radadia K, Moore D, Elsamra S, Singer E, Stein M, Eastham J, Scardino P, Lin Y, Kim I, Lu‐Yao G. Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer. Cancer 2018, 124: 4010-4022. PMID: 30252932, PMCID: PMC6234085, DOI: 10.1002/cncr.31726.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAndrogen AntagonistsAntineoplastic Agents, HormonalCombined Modality TherapyDisease ProgressionDisease-Free SurvivalFollow-Up StudiesHumansMaleOutcome Assessment, Health CareProstatectomyProstatic NeoplasmsRadiotherapy, AdjuvantSEER ProgramSurvival AnalysisTreatment OutcomeUnited StatesConceptsAndrogen deprivation therapyAdvanced prostate cancerRadical prostatectomyProstate cancerDeprivation therapyOverall survivalUrinary incontinenceErectile dysfunctionProstate cancer-specific survivalProstate cancer-specific deathCox proportional hazards modelCancer-specific survivalCancer-specific deathKaplan-Meier methodSEER-Medicare dataProportional hazards modelDifferent treatment approachesHigh rateAdjuvant radiotherapyTreatment armsSurvival outcomesGleason scoreTumor stageClinical guidelinesHigh risk
2017
Predicting clinically significant prostate cancer based on pre-operative patient profile and serum biomarkers
Faiena I, Kim S, Farber N, Kwon Y, Shinder B, Patel N, Salmasi A, Jang T, Singer E, Kim W, Kim I. Predicting clinically significant prostate cancer based on pre-operative patient profile and serum biomarkers. Oncotarget 2017, 5: 109783-109790. PMID: 29312648, PMCID: PMC5752561, DOI: 10.18632/oncotarget.21297.Peer-Reviewed Original ResearchClinical Gleason scoreBody mass indexProstate-specific antigenSignificant prostate cancerProstate acid phosphatasePreoperative prostate-specific antigenGleason scoreProstate cancerSerum biomarkersProstate weightParathyroid hormoneTotal prostate-specific antigenBias-corrected areaMultiple preoperative factorsPreoperative factorsOncologic characteristicsPatient characteristicsProstatectomy databaseMass indexRisk stratificationClinical stageUnivariate analysisPatient profilesHormone profilesMultivariate analysisRisk stratification for disease progression in pT3 prostate cancer after robot-assisted radical prostatectomy
Hong J, Kwon Y, Kim I. Risk stratification for disease progression in pT3 prostate cancer after robot-assisted radical prostatectomy. Asian Journal Of Andrology 2017, 19: 700-706. PMID: 28230003, PMCID: PMC5676431, DOI: 10.4103/1008-682x.193569.Peer-Reviewed Original ResearchConceptsAdjuvant radiation therapyPT3 prostate cancerRobot-assisted radical prostatectomyPathologic Gleason scoreBiochemical recurrenceRadical prostatectomyClinical progressionProstate cancerLymphovascular invasionRisk stratificationRisk factorsDisease progressionMultivariate Cox proportional regression analysisCox proportional regression analysisAdverse pathologic featuresProportional regression analysisRisk stratification toolMore risk factorsStage pT3bFree survivalOncologic outcomesPathologic featuresStratification toolGleason scoreOptimal patientLocal Therapy Improves Overall Survival in Patients With Newly Diagnosed Metastatic Prostate Cancer
Parikh R, Byun J, Goyal S, Kim I. Local Therapy Improves Overall Survival in Patients With Newly Diagnosed Metastatic Prostate Cancer. The Prostate 2017, 77: 559-572. PMID: 28093791, DOI: 10.1002/pros.23294.Peer-Reviewed Original ResearchConceptsNational Cancer DatabaseMetastatic prostate cancerLocal therapyOverall survivalProstate cancerRadiation therapyMultivariable Cox proportional hazards modelsLower co-morbidity scoreFive-year overall survivalCox proportional hazards modelAcademic/research programCo-morbidity scoreSuperior overall survivalNode-negative statusProspective clinical trialsKaplan-Meier methodLower T stagePatterns of careProportional hazards modelPropensity-score matchingPrimary diseaseT stageMedicare insuranceGleason scoreCancer Database
2015
Refining the American Urological Association and American Society for Radiation Oncology guideline for adjuvant radiotherapy after radical prostatectomy using the pathologic Gleason score
Song W, Kwon Y, Jeon S, Kim I. Refining the American Urological Association and American Society for Radiation Oncology guideline for adjuvant radiotherapy after radical prostatectomy using the pathologic Gleason score. Asian Journal Of Andrology 2015, 19: 20-25. PMID: 26620454, PMCID: PMC5227667, DOI: 10.4103/1008-682x.159715.Peer-Reviewed Original ResearchMeSH KeywordsAgedDatabases, FactualDisease-Free SurvivalHumansKallikreinsKaplan-Meier EstimateMaleMargins of ExcisionMiddle AgedNeoplasm GradingNeoplasm Recurrence, LocalNeoplasm StagingPractice Guidelines as TopicProstate-Specific AntigenProstatectomyProstatic NeoplasmsRadiation OncologyRadiotherapy, AdjuvantRetrospective StudiesSocieties, MedicalUnited StatesUrologyConceptsPositive surgical marginsGleason score 6Adjuvant radiotherapyGleason score 8BCR-free survivalRadical prostatectomyBiochemical recurrenceAmerican Urological AssociationPathologic stageGleason scoreScore 6BCR rateSurgical marginsScore 8Urological AssociationPathologic Gleason score 8Multivariate Cox regression analysisPathologic Gleason scoreSurgical margin statusCox regression analysisRadiation Oncology guidelinesAmerican SocietyASTRO guidelineIndependent predictorsMargin statusLower Levels of Human MOB3B Are Associated with Prostate Cancer Susceptibility and Aggressive Clinicopathological Characteristics
Kim E, Kim Y, Kang H, Yoon H, Kim W, Kim Y, Yun S, Moon S, Choi Y, Kim I, Lee S, Kim W. Lower Levels of Human MOB3B Are Associated with Prostate Cancer Susceptibility and Aggressive Clinicopathological Characteristics. Journal Of Korean Medical Science 2015, 30: 937-942. PMID: 26130958, PMCID: PMC4479949, DOI: 10.3346/jkms.2015.30.7.937.Peer-Reviewed Original ResearchConceptsProstate cancerClinicopathological characteristicsElevated prostate-specific antigen levelsProstate-specific antigen levelBenign prostatic hyperplasia patientsNon-metastatic diseaseAggressive clinicopathologic featuresLow PSA levelsSpecific antigen levelsProstatic hyperplasia patientsAggressive clinicopathological characteristicsLow Gleason scoreHuman prostate cancerCharacteristic curve analysisProstate cancer susceptibilityPSA levelsMetastatic diseasePCa patientsClinicopathologic featuresHyperplasia patientsAntigen levelsGleason scoreClinicopathological parametersPCa tissuesReal-time PCRPathologic findings in patients who underwent robot-assisted radical prostatectomy following active surveillance: a prospective study in a single center.
Ha Y, Yu J, Patel N, Hassanzadeh Salmasi A, Parihar J, Kwon T, Kim W, Kim I. Pathologic findings in patients who underwent robot-assisted radical prostatectomy following active surveillance: a prospective study in a single center. Minerva Urologica E Nefrologica 2015, 67: 1-9. PMID: 25664959.Peer-Reviewed Original ResearchConceptsRobot-assisted radical prostatectomyRadical prostatectomyActive surveillanceAdvanced diseaseUnderwent robot-assisted radical prostatectomyLow-risk prostate cancerLower prostate volumePSA density levelsLow-risk diseaseActive surveillance cohortOrgan-confined diseaseSpecimens of patientsAdvanced pathologic featuresProspective cohortAdditional patientsPathologic featuresPathologic findingsProstate volumeSingle centerProspective studyGleason scoreSurveillance cohortDefinitive interventionClinicopathological resultsPathologic analysis
2013
Korean Prostate Cancer Patients Have Worse Disease Characteristics than their American Counterparts
Kang D, Chung J, Ha H, Min K, Yoon J, Kim W, Seo W, Kang P, Jung S, Kim I. Korean Prostate Cancer Patients Have Worse Disease Characteristics than their American Counterparts. Asian Pacific Journal Of Cancer Prevention 2013, 14: 6913-6917. PMID: 24377625, DOI: 10.7314/apjcp.2013.14.11.6913.Peer-Reviewed Original ResearchConceptsBody mass indexHigh Gleason scoreGleason scoreProstate cancerT stageRadical prostatectomyPreoperative prostate-specific antigen levelProstate cancer treatment strategiesProstate-specific antigen levelMean body mass indexKorean prostate cancer patientsMean preoperative PSAWorse disease characteristicsAdvanced prostate cancerPathological T stageHigher T stageProstate cancer patientsHigher PSA valuesMalignant prostate cancerCancer treatment strategiesPreoperative PSAMass indexProstate sizePSA testPSA valuesDiagnostic Role of Prostate Resection in the Elderly Patients Who Experience Significant Co-Morbidity with a High Clinical Suspicion of Prostate Cancer
Kang H, Yang J, Kwon W, Lee Y, Kim W, Kim Y, Yun S, Lee S, Kim I, Kim W. Diagnostic Role of Prostate Resection in the Elderly Patients Who Experience Significant Co-Morbidity with a High Clinical Suspicion of Prostate Cancer. Journal Of Korean Medical Science 2013, 28: 1796-1800. PMID: 24339711, PMCID: PMC3857377, DOI: 10.3346/jkms.2013.28.12.1796.Peer-Reviewed Original ResearchConceptsProstate-specific antigen densityTUR specimensElderly patientsPSA levelsGleason scoreProstate cancerBiopsy coresHigher prostate-specific antigen levelProstate-specific antigen levelElderly comorbid patientsRoutine prostate biopsySignificant co morbiditySpecific antigen densityHigh clinical suspicionSpecific antigen levelsProstatic needle biopsyPrebiopsy PSA levelProstate cancer diagnosisTUR specimenClinical suspicionCo morbiditiesPathologic reviewComorbid patientsTransurethral resectionAntigen levels
2012
Transcriptional repression of RUNX2 is associated with aggressive clinicopathological outcomes, whereas nuclear location of the protein is related to metastasis in prostate cancer
Yun S, Yoon H, Bae S, Lee O, Choi Y, Moon S, Kim I, Kim W. Transcriptional repression of RUNX2 is associated with aggressive clinicopathological outcomes, whereas nuclear location of the protein is related to metastasis in prostate cancer. Prostate Cancer And Prostatic Diseases 2012, 15: 369-373. PMID: 22890388, DOI: 10.1038/pcan.2012.31.Peer-Reviewed Original ResearchConceptsMetastatic diseaseGleason scoreProstate cancerMRNA expressionElevated PSA levelsNon-metastatic diseaseCase-control studyLow Gleason scoreRunx2 expressionHuman prostate tissuePSA levelsBPH patientsClinicopathological characteristicsClinicopathological outcomesCommon cancerLower PSAPrognostic markerReal-time PCRImmunohistochemical stainingImmunohistochemical analysisTranscription factor 2BPH controlProstate tissueRunx2 mRNA expressionCaP aggressiveness
2011
The hOGG1 mutant genotype is associated with prostate cancer susceptibility and aggressive clinicopathological characteristics in the Korean population
Yun S, Ha Y, Chae Y, Kim J, Kim I, Kim W. The hOGG1 mutant genotype is associated with prostate cancer susceptibility and aggressive clinicopathological characteristics in the Korean population. Annals Of Oncology 2011, 23: 401-405. PMID: 21515665, DOI: 10.1093/annonc/mdr115.Peer-Reviewed Original ResearchConceptsAggressive clinicopathological characteristicsClinicopathological characteristicsGleason scoreHOGG1 codon 326 genotypesBenign prostatic hyperplasia patientsSer/Ser genotypeProstatic hyperplasia patientsCase-control studyRisk of CaPPeptide nucleic acid-mediated PCR clampingSer/CysProstate cancer susceptibilityWild-type genotypeCAP patientsMetastatic diseaseClinicopathological outcomesHyperplasia patientsTumor stageProstate cancerHigh riskHOGG1 genotypePatientsSer alleleCys alleleKorean population
2004
Loss of expression of bone morphogenetic protein receptor type II in human prostate cancer cells
Kim I, Lee D, Lee D, Ahn H, Kim M, Kim S, Morton R. Loss of expression of bone morphogenetic protein receptor type II in human prostate cancer cells. Oncogene 2004, 23: 7651-7659. PMID: 15354178, DOI: 10.1038/sj.onc.1207924.Peer-Reviewed Original ResearchConceptsBone morphogenetic proteinProstate cancer cellsHuman prostate cancer cellsLoss of expressionProstate cancer patientsBMP-RIICancer patientsGleason scoreBMP receptor type IABone morphogenetic protein receptor type IICancer cellsSignificant associationHuman prostate cancer cell linesBiochemical recurrence-free rateExpression of BMPRsRecurrence-free rateProstate cancer cell linesCell linesTumor growth rateReceptor type IIParental cell lineCancer cell linesMorphogenetic proteinsClinical stagePrognostic valueTissue expression of transforming growth factor-β1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy
Shariat S, Menesses-Diaz A, Kim I, Muramoto M, Wheeler T, Slawin K. Tissue expression of transforming growth factor-β1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy. Urology 2004, 63: 1191-1197. PMID: 15183988, DOI: 10.1016/j.urology.2003.12.015.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedDisease ProgressionFollow-Up StudiesHumansImmunohistochemistryMaleMiddle AgedMultivariate AnalysisNeoplasm StagingProstateProstate-Specific AntigenProstatectomyProstatic HyperplasiaProstatic NeoplasmsReceptors, Transforming Growth Factor betaTransforming Growth Factor betaTransforming Growth Factor beta1ConceptsPlasma TGF-beta1 levelsTGF-beta1 levelsAbnormal expressionTGFbeta-RIITGFbeta-RIBiochemical progressionRadical prostatectomyProstate cancerPathologic Gleason scoreSeminal vesicle involvementSurgical margin statusProstate cancer featuresTissue expressionGrowth factor-β1TGF-beta1 overexpressionConsecutive patientsExtracapsular diseaseMargin statusPathologic featuresGleason scoreBlood levelsLoss of expressionPrognostic markerImmunohistochemical stainingFactor-β1
1998
Loss of expression of transforming growth factor-beta receptors is associated with poor prognosis in prostate cancer patients.
Kim I, Ahn H, Lang S, Oefelein M, Oyasu R, Kozlowski J, Lee C. Loss of expression of transforming growth factor-beta receptors is associated with poor prognosis in prostate cancer patients. Clinical Cancer Research 1998, 4: 1625-30. PMID: 9676836.Peer-Reviewed Original ResearchConceptsHuman prostate cancer tissuesClinical tumor stageProstate cancer patientsProstate cancer tissuesGleason scoreLoss of expressionTGF-betaRIRecurrence rateTumor stageCancer patientsRadical prostatectomyCancer tissuesSurvival rateSignificant associationPotential prognostic valuePotential prognostic markerReceptor type IGrowth factor betaGrowth factor beta receptorTGF-beta receptorsInitial diagnosisPoor prognosisPrognostic valueDisease progressionPrognostic marker